Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 12274741
Cattle fever tick-infestation vaccines and uses thereof
granted -
US 12269872
Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use
granted -
US 12270814
Kits and methods for prediction and treatment of preeclampsia
granted -
US 12269155
Multivalent vaccines for rabies virus and coronaviruses
granted -
US 12269803
Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease
granted -
US 12268749
Cell-penetrating peptides
granted -
US 12268700
3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof
granted -
US 12268737
Stabilized influenza hemagglutinin stem region trimers and uses thereof
granted -
US 12258372
Recombinant vaccine against Marek's disease and Newcastle disease
granted -
US 12251432
Biomarkers and immunogenic compositions for filarial parasites
granted -
US 12246012
Method for treating nervous system injuries using boldine and derivatives thereof
granted -
US 12239654
Compounds and methods for treating neurological and cardiovascular conditions
granted -
US 12233124
Recombinant metapneumovirus f proteins and their use
granted -
US 12233051
Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
granted -
US 12233087
Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions
granted -
US 12227479
Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury
granted -
US 12226423
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
granted -
US 12227554
Methods for selectively expanding cells expressing a TCR with a murine constant region
granted -
US 12228582
Method and apparatus for testing near infrared-photoimmunotherapy treatment
granted -
US 12221627
Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells
granted -
US 12215164
Immunotoxins with albumin binding domain
granted -
US 12215108
Development of potential antidotes for arsenicals
granted -
US 12215349
Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
granted -
US 12214031
Mannheimia haemolytica vector
granted -
US 12208093
Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
granted -
US 12210017
Peptides representing epitopes from filoviruses
granted -
US 12209142
SARS-CoV-2 epitope-targeted peptide immunostimulants
granted -
US 12201658
Viral gene therapy as treatment for cholesterol storage disease or disorder
granted -
US 12202886
Neutralizing antibodies to GP120 and their use
granted -
US 12202902
FLT3-specific chimeric antigen receptors and methods using same
granted -
US 12201685
Methods of modulating immune responses with cationic lipid vaccine compositions
granted -
US 12195724
Methods of producing T cell populations enriched for stable regulatory T-cells
granted -
US 12188005
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
granted -
US 12186363
Compositions and methods for dengue virus chimeric constructions in vaccines
granted -
US 12187779
Anti-human papillomavirus 16 E6 T cell receptors
granted -
US 12180484
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 12178626
Encapsulated gas or partial vacuum CT contrast material
granted -
US 12180296
Cross species single domain antibodies targeting mesothelin for treating solid tumors
granted -
US 12178907
Binary lipid bilayer-containing vesicles comprising embedded cytotoxic agents and methods of making and using the same
granted -
US 12172038
Anti-coronavirus antibodies and methods of use
granted -
US 12173306
Codon-optimized reduced-size ATP7A CDNA and uses for treatment of copper transport disorders
granted -
US 12173314
Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
granted -
US 12171818
Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
granted -
US 12173021
Treprostinil prodrugs
granted -
US 12168071
Treprostinil derivatives and their use in pharmaceutical compositions
granted -
US 12168675
Virus-like particles and methods of use
granted -
US 12168008
Oxabicycloheptanes for modulation of immune response
granted -
US 12168802
Methods of diagnosing and treating CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE), a newly identified orphan disease
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory